Verrica Pharmaceuticals Inc. (VRCA)

NASDAQ: VRCA · Real-Time Price · USD
5.47
-0.28 (-4.79%)
At close: Aug 22, 2025, 4:00 PM
5.47
0.00 (0.00%)
After-hours: Aug 22, 2025, 4:00 PM EDT
-4.79%
Market Cap52.09M
Revenue (ttm)14.70M
Net Income (ttm)-48.60M
Shares Out 9.45M
EPS (ttm)-6.40
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume50,699
Open5.78
Previous Close5.74
Day's Range5.40 - 5.78
52-Week Range3.82 - 30.19
Beta1.92
AnalystsHold
Price Target60.00 (+987.94%)
Earnings DateAug 12, 2025

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of der... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 2018
Employees 71
Stock Exchange NASDAQ
Ticker Symbol VRCA
Full Company Profile

Financial Performance

In 2024, Verrica Pharmaceuticals's revenue was $7.57 million, an increase of 47.66% compared to the previous year's $5.12 million. Losses were -$76.58 million, 14.3% more than in 2023.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for VRCA stock is "Hold." The 12-month stock price target is $60.0, which is an increase of 987.94% from the latest price.

Price Target
$60.0
(987.94% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jayson M. Rieger - President, CEO & Director John J.

9 days ago - Seeking Alpha

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

–   Company reports $12.7 million in revenue in Q2'25, consisting primarily of $4.5 million in YCANTH ® revenue, net, reflecting sequential growth of 32.5% over Q1'25 and $8.0 million in milestone rev...

10 days ago - GlobeNewsWire

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...

16 days ago - GlobeNewsWire

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH ® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from...

6 weeks ago - GlobeNewsWire

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule –

7 weeks ago - GlobeNewsWire

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disease...

3 months ago - GlobeNewsWire

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q1 2025 Corporate Update Conference Call May 13, 2025 4:30 PM ET Company Participants Kevin Gardner - Managing Director LifeSci Advisors Jayson Rieger - Pr...

3 months ago - Seeking Alpha

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7%...

3 months ago - GlobeNewsWire

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disease...

3 months ago - GlobeNewsWire

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disea...

4 months ago - GlobeNewsWire

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disea...

5 months ago - GlobeNewsWire

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disea...

5 months ago - GlobeNewsWire

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disea...

5 months ago - GlobeNewsWire

Verrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call Transcript

Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants John Fraunces - Director, Corporate Communications, LifeSci Advisors, IR Ja...

5 months ago - Seeking Alpha

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4'24 concurrent with significantly lower operating expenses –

5 months ago - GlobeNewsWire

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin disea...

6 months ago - GlobeNewsWire

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...

6 months ago - GlobeNewsWire

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...

9 months ago - GlobeNewsWire

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...

9 months ago - GlobeNewsWire

Verrica Announces Pricing of $42.0 Million Public Offering

WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...

9 months ago - GlobeNewsWire

Verrica Announces Proposed Public Offering

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseas...

9 months ago - GlobeNewsWire

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

SAN FRANCISCO , Oct. 30, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Verrica Pharmaceuticals Inc. investors that the firm is investigating potential legal claims relating to the compan...

10 months ago - PRNewsWire

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance -

10 months ago - GlobeNewsWire

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...

11 months ago - Business Wire

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermato...

11 months ago - GlobeNewsWire